Market Cap: $14.53B
HI
Halozyme Therapeutics, Inc.
HALO
NASDAQ (NASDAQ Global Select)USD
Market Cap: $14.53B
Halozyme Therapeutics (Ticker: HALO) leverages its innovative ENHANZE technology to transform the delivery of biologic drugs, marking a significant advancement in the pharmaceutical industry. The grow…
Halozyme Therapeutics (Ticker: HALO) indicates it anticipates minimal disruption to its royalty revenues, extending through 2035, following the proposed CMS Medicare Drug Price Negotiation Program. Dr…
Halozyme Therapeutics (Ticker: HALO) continues to advance its innovative position in the biopharmaceutical landscape, particularly following recent developments related to its ENHANZE drug delivery te…
Halozyme Therapeutics (Ticker: HALO) has made a significant stride in the biopharmaceutical industry through a major collaboration with GSK, announced on May 7, 2026. This partnership grants GSK acces…
Halozyme Therapeutics Appoints David Ramsay as Interim CFO Halozyme Therapeutics, Inc. announces the appointment of David Ramsay as Interim Chief Financial Officer (CFO), a decision that looks to bols…
Halozyme Therapeutics Signals Leadership Confidence Amid Insider Sale In a recent disclosure to the Securities and Exchange Commission (SEC), Cortney Caudill, the Senior Vice President of Halozyme The…
Halozyme Therapeutics: Bridging Innovation and Leadership Insight Amid Market Sensitivity Halozyme Therapeutics, a prominent player in the biopharmaceutical landscape, operates at the cutting edge of…
Innovative Technology in Electric Marine Power: Blade Outboards Launches Halo Connect Platform Blade Outboards, committed to revolutionizing marine propulsion with electric technology, introduces the…
Outdoor-styled pet tracker highlights platform and partnership strategies relevant to drug‑delivery firms Lifestyle tie-up around Halo Collar 5 exemplifies how device-plus-software products leverage b…
Halozyme Therapeutics Unveils Innovative Pricing Strategy to Benefit Customers Halozyme Therapeutics, a leader in the biotechnology sector specializing in drug delivery solutions, is making waves with…
Halozyme Therapeutics Advances Customer-Centric Innovation with ARR Milestones Program Halozyme Therapeutics introduces its groundbreaking pricing initiative, the ARR Milestones program, aiming to res…
Halozyme and Skye Bioscience Forge Innovative Collaboration to Combat Obesity Halozyme Therapeutics, Inc. has recently partnered with Skye Bioscience, Inc. in a groundbreaking global collaboration aim…
Oncolytics Biotech's Breakthrough in Gastrointestinal Cancer Treatment Oncolytics Biotech Inc. is poised to revolutionize the treatment landscape for gastrointestinal cancers, especially those traditi…
Oncolytics Biotech: Pioneering New Frontiers in Gastrointestinal Cancer Treatment Oncolytics Biotech Inc. is at the forefront of a transformative shift in the treatment of gastrointestinal cancers, pa…
Halozyme Secures Legal Victory Against Merck in Patent Dispute Halozyme Therapeutics, Inc. announces a significant legal development as a German court issues a preliminary injunction against Merck, pr…
Halozyme Therapeutics: Pioneering Innovations in Drug Delivery Systems Halozyme Therapeutics is at the forefront of transforming drug delivery systems, particularly through its proprietary Enhanze™ te…
Halozyme Therapeutics: Pioneering Advanced Drug Delivery Solutions Halozyme Therapeutics, Inc., a biopharmaceutical leader based in San Diego, is poised to showcase its innovative approaches to drug d…
Halozyme Therapeutics Expands Drug Delivery Capabilities Through Strategic Collaborations Halozyme Therapeutics, Inc. announces a significant global collaboration with Merus N.V. aimed at enhancing ca…
Halozyme Therapeutics Gains FDA Approval for Innovative Treatment in Multiple Myeloma Halozyme Therapeutics, Inc. announces a significant milestone with the FDA approval of DARZALEX Faspro® (daratumum…
Halozyme Therapeutics Secures $1.3 Billion Through Convertible Senior Notes Halozyme Therapeutics, Inc. embarks on a significant financing initiative, announcing the pricing of two series of convertib…
Halozyme Therapeutics Expands Financial Strategy with Convertible Senior Notes Offering Halozyme Therapeutics, Inc. announces a significant move in its financial strategy by offering $650 million in c…
Halozyme Therapeutics Strengthens Financial Position with Convertible Senior Notes Offering Halozyme Therapeutics, Inc. announces its plan to raise $650 million through the issuance of convertible sen…
Halozyme Therapeutics Prepares for Key Earnings Report Amid Product Development Focus Halozyme Therapeutics is on the brink of releasing its quarterly earnings report on November 3, 2025, a moment tha…
Revolutionizing School Transportation: First Student's HALO™ Platform Earns Industry Recognition First Student, a prominent name in the innovative school transportation sector, garners attention with…
First Student Revolutionizes K-12 Transportation with HALO™ Platform First Student, a leader in innovative school transportation, earns the Fast Company’s Next Big Thing in Tech Award for its groundbr…